0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Picture of the Month FREE

Arch Pediatr Adolesc Med. 1999;153(1):87-88. doi:.
Text Size: A A A
Published online

Figure 1. The lips are swollen and 2 shallow ulcers are visible on the undersurface of the tongue.

Figure 2. A discrete petechial rash is present on the feet.

Figure 3. A discrete petechial rash is present on the hand and the fingers are swollen.

Parvovirus B19, discovered in 1974, is a small, nonenveloped, single-stranded DNA virus, belonging to the family Parvoviridae.1,2 Infection with Parvovirus B19 is common. The prevalence of IgG antibodies to the virus ranges from 2% to 15% in children from 1 to 5 years of age and from 30% to 60% in adults.3,4 Clinical infection with this virus is most common in school-aged children. The mode of spread is believed to be by respiratory droplets. Secondary spread among susceptible household members occurs in about 50% of contacts.3

In the immunologically normal host, Parvovirus B19 infection may be asymptomatic, may result in erythema infectiosum (fifth disease), or may induce arthritis.5,6 Erythema infectiosum, characterized by the "slapped cheek" appearance and lacey erythema of the proximal extremities, is the most common clinical manifestation of Parvovirus B19 infection and occurs most frequently in school-aged children. Once the rash appears, the children are no longer capable of transmitting the disease.

Petechial rashes, with or without thrombocytopenia and vesiculobullous lesions, have also been associated with Parvovirus B19 infections.7,8 More recently, a distinctive exanthem known as the papular-purpuric "gloves and socks" or the petechial gloves and socks syndrome has been described in older children and adults, many of whom have demonstrated evidence of Parvovirus B19 infection.911 The clinical picture of this illness is characterized by pruritic edema and erythema of the hands and feet in a gloves and socks distribution, oral lesions, and fever, followed by the rapid development of petechiae on the hands and feet.

Parvovirus B19 may cause an aplastic crisis in patients with chronic hemolytic anemias. Although megakaryocytes and myeloid cells are not infected, neutropenia, thrombocytopenia, or both are commonly found in these patients.12,13 In patients with immunodeficiency, congenital or acquired, Parvovirus B19 infection may become chronic, resulting in persistent viremia and bone marrow failure. Most of these immunodeficient patients do not experience the rash, fever, or polyarthropathy frequently associated with this infection.14

Parvovirus B19 infection has also been implicated as a possible cause of idiopathic thrombocytopenic purpura. In a series of 35 previously healthy children with classic idiopathic thrombocytopenic purpura, almost half had evidence of Parvovirus B19 DNA in peripheral blood or bone marrow, while none of 14 control patients had polymerase chain reaction or anti–B19 IgM antibodies.15Parvovirus B19 infection also accounts for as much as one fourth of the cases of nonimmune fetal hydrops by causing red blood cell aplasia.16

In addition, Parvovirus B19 has been demonstrated to be a cause of arthritis, chronic encephalitis, and aseptic meningitis among otherwise normal children.6

In the healthy host, detection of IgM antibodies to Parvovirus B19 denotes a recent infection. Both IgM and IgG antibodies are present soon after the onset of illness and reach peak titers in the first 30 days. IgG antibodies persist for years, but IgM antibody levels begin to decline 30 to 60 days after the onset of the illness. Hybridization techniques or polymerase chain reaction may also be useful in detecting Parvovirus B19 infection. These techniques have been used to detect viral DNA in clinical samples of serum, urine, respiratory secretions, and body tissues.

Antiviral therapy for this infection is unavailable. For most patients, supportive care only is indicated. Intravenous immunoglobulin therapy may be effective in treating Parvovirus B19 infection in immunodeficient patients.14

Accepted for publication September 5, 1997.

Reprints: Basim Asmar, MD, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI 48201-2196.

Cossart  YEField  AMCant  BWiddows  D Parvovirus-like particles in human sera. Lancet. 1975;172- 73
Link to Article
Brown  KEYoung  NSLiu  JM Molecular, cellular and clinical aspects of Parvovirus B19 infection. Crit Rev Oncol Hematol. 1994;161- 31
Link to Article
Anderson  LJ Role of Parvovirus B19 in human disease. Pediatr Infect Dis J. 1987;6711- 718
Link to Article
Koch  WCAdler  SP Human Parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J. 1989;883- 87
Bell  LMNaides  SJStoffman  PHodinka  RLPlotkin  SA Human Parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321485- 491
Link to Article
Nocton  JJMiller  LCTucker  LBSchaller  JG Human Parvovirus B19-associated arthritis in children. J Pediatr. 1993;122186- 190
Link to Article
Hogan  PA Viral exanthems in childhood. Aust J Dermatol. 1996;37(suppl)514- 516
Link to Article
Lefrere  JJCourouce  AMKaplan  C Parvovirus and idiopathic thrombocytopenic purpura [letter]. Lancet. 1989;1279
Link to Article
Harms  MFeldman  RSaurat  JH Papular-purpuric "gloves and socks" syndrome. J Am Acad Dermatol. 1990;23850- 854
Link to Article
Halasz  CLGCormier  DDen  M Petechial glove and sock syndrome caused by Parvovirus B19. J Am Acad Dermatol. 1992;27835- 838
Link to Article
Stone  MSMurph  JR Papular-purpuric gloves and socks syndrome: a characteristic viral exanthem. Pediatrics. 1993;92864- 865
Mustafa  MMMcClain  KL Diverse hematologic effects of Parvovirus B19 infection. Pediatr Clin North Am. 1996;43809- 821
Link to Article
Muir  KTodd  WTWatson  WHFitzsimmons  E Viral-associated haemophagocytosis with Parvovirus-B19–related pancytopenia. Lancet. 1992;3391139- 1140
Link to Article
Koch  WCMassey  GRussell  CEAdler  SP Manifestations and treatment of human Parvovirus B19 infection in immunocompromised patients. J Pediatr. 1990;116355- 359
Link to Article
Murray  JCKelley  PKHogrefe  WRMcClain  KL Childhood idiopathic thrombocytopenic purpura: association with human Parvovirus B19 infection. Am J Pediatr Hematol Oncol. 1994;16314- 319
Anand  AGray  ESBrown  TClewley  JPCohen  BJ Human Parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316183- 186
Link to Article

Tables

References

Cossart  YEField  AMCant  BWiddows  D Parvovirus-like particles in human sera. Lancet. 1975;172- 73
Link to Article
Brown  KEYoung  NSLiu  JM Molecular, cellular and clinical aspects of Parvovirus B19 infection. Crit Rev Oncol Hematol. 1994;161- 31
Link to Article
Anderson  LJ Role of Parvovirus B19 in human disease. Pediatr Infect Dis J. 1987;6711- 718
Link to Article
Koch  WCAdler  SP Human Parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J. 1989;883- 87
Bell  LMNaides  SJStoffman  PHodinka  RLPlotkin  SA Human Parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321485- 491
Link to Article
Nocton  JJMiller  LCTucker  LBSchaller  JG Human Parvovirus B19-associated arthritis in children. J Pediatr. 1993;122186- 190
Link to Article
Hogan  PA Viral exanthems in childhood. Aust J Dermatol. 1996;37(suppl)514- 516
Link to Article
Lefrere  JJCourouce  AMKaplan  C Parvovirus and idiopathic thrombocytopenic purpura [letter]. Lancet. 1989;1279
Link to Article
Harms  MFeldman  RSaurat  JH Papular-purpuric "gloves and socks" syndrome. J Am Acad Dermatol. 1990;23850- 854
Link to Article
Halasz  CLGCormier  DDen  M Petechial glove and sock syndrome caused by Parvovirus B19. J Am Acad Dermatol. 1992;27835- 838
Link to Article
Stone  MSMurph  JR Papular-purpuric gloves and socks syndrome: a characteristic viral exanthem. Pediatrics. 1993;92864- 865
Mustafa  MMMcClain  KL Diverse hematologic effects of Parvovirus B19 infection. Pediatr Clin North Am. 1996;43809- 821
Link to Article
Muir  KTodd  WTWatson  WHFitzsimmons  E Viral-associated haemophagocytosis with Parvovirus-B19–related pancytopenia. Lancet. 1992;3391139- 1140
Link to Article
Koch  WCMassey  GRussell  CEAdler  SP Manifestations and treatment of human Parvovirus B19 infection in immunocompromised patients. J Pediatr. 1990;116355- 359
Link to Article
Murray  JCKelley  PKHogrefe  WRMcClain  KL Childhood idiopathic thrombocytopenic purpura: association with human Parvovirus B19 infection. Am J Pediatr Hematol Oncol. 1994;16314- 319
Anand  AGray  ESBrown  TClewley  JPCohen  BJ Human Parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316183- 186
Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 4

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles